Published in Cancer Weekly, January 21st, 2003
Specifically, Keryx believes that the mechanism of a pre-IND meeting will enable the company to discuss with the FDA matters related to the formulation strategy for the clinical trials of KRX-123. As the company has previously stated, Keryx had encountered challenges in formulating KRX-123.
Recently, Keryx has developed several innovative approaches for formulating KRX-123...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.